Brevan Howard Capital Management LP Invests $150,000 in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Brevan Howard Capital Management LP acquired a new position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 25,061 shares of the company’s stock, valued at approximately $150,000.

A number of other institutional investors have also made changes to their positions in ADPT. Barclays PLC grew its position in Adaptive Biotechnologies by 149.5% during the third quarter. Barclays PLC now owns 230,177 shares of the company’s stock worth $1,180,000 after buying an additional 137,936 shares in the last quarter. GAMMA Investing LLC acquired a new stake in Adaptive Biotechnologies during the fourth quarter worth about $59,000. SG Americas Securities LLC grew its position in Adaptive Biotechnologies by 11.7% during the fourth quarter. SG Americas Securities LLC now owns 45,944 shares of the company’s stock worth $275,000 after buying an additional 4,799 shares in the last quarter. Impact Partnership Wealth LLC grew its position in Adaptive Biotechnologies by 8.8% during the fourth quarter. Impact Partnership Wealth LLC now owns 19,078 shares of the company’s stock worth $114,000 after buying an additional 1,539 shares in the last quarter. Finally, KBC Group NV acquired a new stake in Adaptive Biotechnologies during the fourth quarter worth about $50,000. 99.17% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Robert Hershberg sold 53,000 shares of Adaptive Biotechnologies stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $7.59, for a total value of $402,270.00. Following the completion of the transaction, the director now owns 69,690 shares in the company, valued at approximately $528,947.10. The trade was a 43.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Chad M. Robins sold 211,160 shares of Adaptive Biotechnologies stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $8.50, for a total transaction of $1,794,860.00. Following the completion of the transaction, the chief executive officer now owns 2,576,701 shares of the company’s stock, valued at $21,901,958.50. This trade represents a 7.57% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 826,013 shares of company stock worth $6,543,452. Insiders own 6.20% of the company’s stock.

Adaptive Biotechnologies Trading Up 5.3%

NASDAQ ADPT opened at $9.51 on Tuesday. The stock’s 50 day moving average is $7.86 and its two-hundred day moving average is $7.07. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -8.72 and a beta of 1.75. Adaptive Biotechnologies Co. has a 1-year low of $2.99 and a 1-year high of $10.28.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Thursday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.08. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. The company had revenue of $52.44 million during the quarter, compared to analysts’ expectations of $42.13 million. During the same quarter in the previous year, the company posted ($0.33) earnings per share. Adaptive Biotechnologies’s quarterly revenue was up 25.2% compared to the same quarter last year. On average, analysts predict that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Scotiabank lifted their target price on Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 13th. The Goldman Sachs Group lifted their target price on Adaptive Biotechnologies from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $13.00 price objective (up from $11.00) on shares of Adaptive Biotechnologies in a report on Tuesday, May 6th. Finally, Morgan Stanley lifted their price objective on Adaptive Biotechnologies from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Monday, May 5th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.83.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.